Tag Archives: acute myocardial infarction
June 2020 Br J Cardiol 2020;27:51–54 doi:10.5837/bjc.2020.017
Impact of COVID-19 on primary percutaneous coronary intervention centres in the UK: a survey
Ahmed M Adlan, Ven G Lim, Gurpreet Dhillon, Hibba Kurdi, Gemina Doolub, Nadir Elamin, Amir Aziz, Sanjay Sastry, Gershan Davis
Introduction Coronavirus disease-2019 (COVID-19) was declared a pandemic by the World Health Organization on 12th March 2020.1 Subsequently, on 20th March 2020, the National Health Service (NHS) England in collaboration with the British Cardiovascular Society (BCS), the British Cardiovascular Interventional Society (BCIS) and the British Heart Rhythm Society (BHRS) published guidelines for the management of cardiology patients during the coronavirus pandemic.2 Briefly, the guidelines recommended that: all non-urgent elective inpatient/day case procedures should be postponed primary percutaneous coronary intervention (PCI) should continue to b
September 2017 Br J Cardiol 2017;24(suppl 1):S3–S9 doi:10.5837/bjc.2017.s01
Acute coronary syndrome in adults: scope of the problem in the UK
Chris P Gale
Definition of ACS Acute coronary syndromes (ACS) include unstable angina and acute myocardial infarction (AMI). AMI is classified according to those patients with electrocardiographic ST-segment elevation, ST-elevation myocardial infarction (STEMI) and those without electrocardiographic ST-segment elevation, non-ST-elevation myocardial infarction (NSTEMI).1 The requirement for a diagnosis of AMI in the universal definition is the detection of troponin release from injured cardiac myocytes with at least one value >99th centile of the upper reference limit.1 Diagnosis is confirmed only if this is associated with at least one of: symptoms of
October 2015 Br J Cardiol 2015;22:138–142
News from the European Society of Cardiology Congress 2015
BJCardio Staff
(more…)
March 2013 Br J Cardiol 2013;20:32–7 doi:10.5837/bjc.2013.007
Primary angioplasty for acute STEMI in secondary care: feasibility, outcomes and potential advantages
Andrew Whittaker, Lee Rowell, Olayiwola Olatawura, Petra Poliacikova, Jason Glover, Carl I Brookes, Andrew J Bishop
Introduction On inference from a range of randomised clinical trials, timely primary percutaneous coronary intervention (PPCI) has become the optimal strategy for the treatment of ST-segment elevation myocardial infarction (STEMI).1-8 Despite the logistic complexity and potential for delay compared with fibrinolytic treatment, the standard outcomes of safety and effectiveness of PPCI are superior to fibrinolysis unless the time delay is substantial.9-12 These data have led to the decision that, not only should PPCI be the treatment of choice for STEMI in England, it must be available 24 hours per day, seven days per week.13 This generates log
July 2010 Br J Cardiol 2010;17:185-9
‘Time is muscle’: aspirin taken during acute coronary thrombosis
Peter C Elwood, Gareth Morgan, Malcolm Woollard, Andrew D Beswick
Introduction Aspirin, used in vascular disease prophylaxis, is probably the most cost-effective drug available in clinical practice and daily low-dose aspirin is now a standard item in the long-term management of vascular disease. Within a public health context, the provision of aspirin to individuals at increased vascular risk has been judged to be the preventive activity of greatest benefit and at the lowest cost (by far), apart from smoking cessation.1 Patients with known vascular disease are clearly at increased vascular risk, and a recent US Task Force judged that ‘individuals at increased risk’ includes males aged over about 45 and
July 2005 Br J Cardiol (Acute Interv Cardiol) 2005;12:AIC 56–AIC 59
Introduction of primary percutaneous coronary intervention for ST elevation myocardial infarction in a district general hospital
Sohail Qaisar, Melanie Fellows, Hannah Whitlam, Rumi Jaumdally, James M Beattie, Patricia J Lowry, Nadia El-Gaylani, Robert G Murray, Jerome Ment, Michael Pitt
No content available
May 2005 Br J Cardiol 2005;12:205-8
Heart failure after myocardial infarction: a neglected problem?
Martin R Cowie, Larry Lacey, Maggie Tabberer
No content available
July 2004 Br J Cardiol (Acute Interv Cardiol) 2004;11:AIC 68–AIC 69
Isolated ventricular non-compaction presenting as acute myocardial infarction
Divaka Perera, Dudley J Pennell, Barry J Kneale
No content available
January 2004 Br J Cardiol 2004;11:39-41
Redefining acute MI: the potential impact on rehabilitation services
Mark Snowden
No content available
May 2003 Br J Cardiol 2003;10:212-3
Use of nicotine replacement therapy early in recovery post-acute myocardial infarction to aid smoking cessation
Katherine A Willmer, Valerie Bell
No content available
For healthcare professionals only
